Person pricking a fingertip with a lancing device beside a glucose meter and test strip

Dawn Phenomenon: Why Morning Blood Sugar Runs High, 5 Steps to Discuss

Key Takeaways

  • The ADA says approximately half of people with type 1 or type 2 diabetes experience the dawn phenomenon, which raises glucose between about 3 and 8 a.m.[1]
  • The ADA names two main causes of morning highs, the dawn phenomenon and waning insulin. It calls the Somogyi effect much rarer.[1][2]
  • Checking at bedtime, overnight and on waking, or using a sensor, shows your pattern.[1]
  • Five steps have some support in the research, and none is shown to remove the effect.[1][3]

Why is your reading higher at 7 a.m. than at bedtime when you ate nothing overnight? The dawn phenomenon may be the answer. The ADA says hormones including cortisol and growth hormone signal the liver to boost glucose production. It says approximately half of people with type 1 or type 2 diabetes experience it.[1]

This guide explains the dawn phenomenon and how it differs from the Somogyi effect. It shows how to check for it. It also covers five steps the research supports in some way. Each step has limits.

This guide is general education. If you use insulin or other glucose medicines, follow the plan your diabetes team gave you.

What is the dawn phenomenon?

The dawn phenomenon is an early-morning rise in blood glucose. The ADA says it raises glucose between approximately 3 and 8 a.m.[1] A review of the literature put it at about 54% of people with type 1 and 55% with type 2 diabetes.[3] Estimates vary because studies define it differently.

That review calls the rise clinically relevant when glucose climbs by more than 10 mg/dL (0.6 mmol/L). Insulin needs rising by at least 20% counts too.[3] It points to growth hormone as a likely driver, through weaker insulin sensitivity at the liver and muscles.[3]

Why is my blood sugar high in the morning?

A morning blood sugar spike has several possible causes. The ADA names two main culprits, the dawn phenomenon and waning insulin. It calls the Somogyi effect "a much rarer cause."[1] Waning insulin means the dose taken the evening before wears off by morning. Late dinners may play a part too.[4]

One high reading does not make a pattern. The ADA says an occasional morning high has little impact on A1C.[1] The table compares the usual suspects.

Morning highs at a glance

Item. What the evidence says. Practical point.
Dawn phenomenon. Cortisol and growth hormone signal the liver to boost glucose production.[1] Check readings at bedtime, in the night and on waking.[1]
Waning insulin. Insulin taken the evening before can wear off by morning. The ADA lists it as a main cause, together with the dawn phenomenon.[1] Tell your prescriber if morning highs repeat. Never change insulin on your own.[1]
Somogyi effect. The ADA calls it a much rarer cause.[1] A type 1 sensor study said it is rare in clinical practice.[2] Ask about overnight lows before any insulin change.[2][3]
Late dinner. Among 409 people with type 2 diabetes, dinner after 8 p.m. went with A1C of 58.1 vs 55.2 mmol/mol (7.5% vs 7.2%), P = 0.023, after adjustment. It was a cross-sectional study.[4] An association only. The study did not measure the dawn effect.[4]
Bedtime dose increase. A review notes that raising bedtime doses of diabetes medicines that peak at night may correct morning highs but can bring night-time lows.[3] Never change a dose on your own.[3]

How common is the dawn phenomenon in type 2 diabetes?

Dawn phenomenon type 2 diabetes data come mostly from sensor studies. They show it is common. The size varies. In 248 people not on insulin who wore a continuous glucose monitor (CGM), the median dawn rise was 16.0 mg/dL (0.9 mmol/L). Its effect on HbA1c was about 0.4%, roughly 4 mmol/mol.[5]

A CGM study of 306 Chinese adults found prevalence between 31.5% and 42.5% across three oral drug groups.[6] The 2013 authors noted the phenomenon was "not eliminated by any of the currently available armamentarium of oral antidiabetes agents."[5] That statement is more than a decade old.

In type 1 diabetes, 17 of 33 people (52%) in two insulin pump trials had it. Onset was around 3 a.m. That sample was small.[7]

Dawn phenomenon or Somogyi effect: how do you tell?

The Somogyi effect is the idea that a night-time low triggers a rebound high. In 89 adults with type 1 diabetes wearing CGM, the authors concluded that "in clinical practice, the Somogyi effect is rare."[2] That evidence is from type 1. The sources reviewed here contain no CGM-confirmed trial of the Somogyi effect in type 2 diabetes.

Dawn phenomenon vs Somogyi effect: telling them apart comes down to what happens in the night. The same study found nocturnal hypoglycaemia on 94% of nights when fasting capillary glucose was below 5 mmol/L (90 mg/dL).[2] Fasting readings were smaller after nights with a low, not higher.[2] A fasting reading above 10 mmol/L (180 mg/dL) followed a night-time low on only two occasions.[2]

So a night-time low is a reason to look for more lows. It is not a reason to expect a rebound high. Learn the signs in our guide to low blood sugar.

This matters for safety. A review notes that raising bedtime doses of insulin or a sulfonylurea such as gliclazide or glimepiride to chase morning highs can bring night-time lows.[3][8] Low blood sugar usually means below 4 mmol/L (72 mg/dL) in the UK or below 70 mg/dL (3.9 mmol/L) in the US.[8][9] Do not raise a dose because of a high morning number. In the UK, the NHS says to call 999 if someone may have very low blood sugar and is not responding normally or is unconscious, and a glucagon injection is not available or you do not know how to use it, or they have not recovered within 10 minutes of a glucagon injection, or they have been drinking alcohol.[8] In the US, the ADA says to call 911 right away if someone is unconscious and glucagon is not available or no one knows how to use it.[9]

How do you check whether you have the dawn phenomenon?

The ADA advises checking at bedtime, in the middle of the night and first thing when you wake up. A CGM is another option.[1] In 210 people with type 2 diabetes on CGM, a rise of 20 mg/dL (1.1 mmol/L) defined the dawn effect. Finger-prick readings before meals could predict it.[10]

That study compared the pre-breakfast reading with the average of the pre-lunch and pre-dinner readings. A difference of 10 mg/dL (0.6 mmol/L) was its marker.[10] Sensor reports add terms worth knowing. Time below range means under 70 mg/dL (3.9 mmol/L) or under 54 mg/dL (3.0 mmol/L).[11]

Our pages on self-monitoring and glucose sensors explain the tools. Take your log to your clinician. For context, the ADA sets a general pre-meal and fasting capillary target of 80 to 130 mg/dL (4.4 to 7.2 mmol/L) for many nonpregnant adults, while Diabetes UK lists a general pre-meal target of 4 to 7 mmol/L (72 to 126 mg/dL) for type 2 diabetes and 5 to 7 mmol/L (90 to 126 mg/dL) on waking for type 1 diabetes, though your clinician sets your personal target.[11][12]

Pro Tip

If you do not wear a continuous glucose sensor, the ADA suggests checking your blood sugar once before bed, once in the middle of the night, and first thing when you wake up. Alongside those three readings, jot down what time you ate dinner and when you took your evening medicines so your prescriber can see the full picture.[1][10]

What can help steady morning numbers?

No self-care step has been shown to remove the dawn phenomenon. In the 248-person CGM study the median rise was 16.0 mg/dL (0.9 mmol/L). No oral agent available then eliminated it.[5] The five steps below have some support in the sources, and each has limits. Talk to your clinician before changing a dose.

  1. Map your pattern first. Log bedtime, overnight and waking readings, or use a sensor, as the ADA describes.[1][10]
  2. Plan exercise with the time of day in mind. The ADA calls morning exercise "a good idea for anyone experiencing the dawn phenomenon" and warns that "if you work out before bed, you risk going low overnight."[1] One crossover trial involved adults with obesity and impaired fasting glucose, without type 2 diabetes; exercise at any time delayed the evening rise in glucose, though it did not change morning fasting glucose.[13]
  3. Break up long sitting. In 24 adults with type 2 diabetes, nocturnal glucose was 10.6 mmol/L (191 mg/dL) after uninterrupted sitting and about 8.1 to 8.3 mmol/L (146 to 149 mg/dL) with light walking or simple resistance breaks, and waking glucose differed by 2.7 mmol/L (49 mg/dL) in the same comparison, though the trial was small and did not measure the dawn effect.[14]
  4. Avoid very late dinners. Beyond the cross-sectional A1C link above, a tiny crossover trial in 8 patients found a 9 p.m. dinner gave a bigger 2-hour glucose response than a 6 p.m. dinner, 449 vs 216 mmol/L x min (about 8,082 vs 3,888 mg/dL x min), without measuring the dawn effect; ask your clinician before moving meals if you take diabetes medicine.[4][15]
  5. Ask your prescriber about medicine timing, bring your readings to your appointment, and never change your dose or timing on your own.[3][16][17]

Medicine timing is set by your prescriber. Labels for each metformin product give their own dosing times.[16][17] Do not change your timing or dose on your own.

Questions to ask your diabetes team

  • Do my bedtime, overnight and waking readings point to the dawn phenomenon, waning insulin or overnight lows?[1][2][3]
  • What is my personal fasting blood glucose target on waking?[11][12]
  • Would a continuous glucose monitor (CGM) help us see what happens to my blood sugar between 3 and 8 a.m.?[1][10][11]
  • Should we adjust the timing or type of my evening diabetes medicine, or would shifting dinner or exercise time be safer to try first?[1][3][15]

Frequently asked questions

What time does the dawn phenomenon happen?

Between approximately 3 and 8 a.m. The ADA says it raises blood glucose during those early-morning hours.[1] In 33 people with type 1 diabetes in two insulin pump trials, onset was at 3 a.m. The sample was small.[7] Your own timing can be seen with overnight readings or a sensor.

Is the dawn phenomenon the same as the Somogyi effect?

No. The dawn phenomenon is a hormone-driven morning rise. The Somogyi effect is a proposed rebound after a night-time low, which the ADA calls a much rarer cause.[1] In 89 adults with type 1 diabetes on CGM, researchers called it rare in clinical practice.[2]

Does everyone with diabetes have the dawn phenomenon?

No. The ADA says approximately half of people with type 1 or type 2 diabetes experience it.[1] In 306 Chinese adults with type 2 diabetes on CGM, prevalence was between 31.5% and 42.5% across three oral drug groups.[6] Results come from specific groups.

Should I change my metformin or insulin timing for morning highs?

Not on your own. A review notes that raising bedtime doses of diabetes medicines that peak at night may correct morning highs but can bring night-time lows.[3] Medicine timing is a decision for your prescriber. Bring your bedtime, overnight and waking readings.

Where to go next

For more on how overnight habits and long-term lab numbers fit together, see:

Note: If you are pregnant, breastfeeding, or considering giving any supplement or herbal product to a child, consult your healthcare provider before making any changes to your diet, supplement routine, or prescribed medications.

Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Talk to your doctor before changing your diet, your activity or your medicines, and before starting any supplement.

Sources & References

  1. American Diabetes Association. High Morning Blood Glucose. Checked 25 October 2026. diabetes.org/living-with-diabetes/high-morning-blood-glucose
  2. Choudhary P, Davies C, Emery CJ, Heller SR (2013). Do high fasting glucose levels suggest nocturnal hypoglycaemia? The Somogyi effect-more fiction than fact? Diabetic Medicine, 30(8), 914-917. PMID: 23672623. Funded by Diabetes UK; Medtronic provided CGMS monitors and sensors. One author reported speaker fees and advisory board ties with Medtronic, Novo Nordisk, Eli Lilly and Sanofi. pubmed.ncbi.nlm.nih.gov/23672623
  3. Carroll MF, Schade DS (2005). The dawn phenomenon revisited: implications for diabetes therapy. Endocrine Practice, 11(1), 55-64. PMID: 16033737. Funding and conflicts of interest not stated in the PubMed record; full text not checked. pubmed.ncbi.nlm.nih.gov/16033737
  4. Sakai R, Hashimoto Y, Ushigome E, et al. (2018). Late-night-dinner is associated with poor glycemic control in people with type 2 diabetes: The KAMOGAWA-DM cohort study. Endocrine Journal, 65(4), 395-402. PMID: 29375081. No specific external funding; several authors reported grants or speaker fees from Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca and Merck outside the submitted work. pubmed.ncbi.nlm.nih.gov/29375081
  5. Monnier L, Colette C, Dejager S, Owens D (2013). Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern? Diabetes Care, 36(12), 4057-4062. PMID: 24170753. One author was an employee of Novartis Pharma AG; the other authors declared no other duality of interest (PMC full text). pubmed.ncbi.nlm.nih.gov/24170753
  6. Wu Z, Jin S, Yu X, et al. (2017). Self-monitoring of blood glucose to assess dawn phenomenon in Chinese people with type 2 diabetes mellitus. International Journal of Endocrinology, 2017, 7428748. PMID: 28421112. Funded by the National Key R&D Program of China and National Natural Science Foundation of China; the authors declared no conflicts of interest (PMC full text). pubmed.ncbi.nlm.nih.gov/28421112
  7. Ostrovski I, Lovblom LE, Scarr D, et al. (2020). Analysis of prevalence, magnitude and timing of the dawn phenomenon in adults and adolescents with type 1 diabetes: descriptive analysis of 2 insulin pump trials. Canadian Journal of Diabetes, 44(3), 229-235. PMID: 31630987. Supported by JDRF and Canadian Institutes of Health Research; several authors reported grants or speaker fees from Medtronic, Eli Lilly, Novo Nordisk and Sanofi. pubmed.ncbi.nlm.nih.gov/31630987
  8. NHS (reviewed 3 August 2023). Low blood sugar (hypoglycaemia). Checked 25 October 2026. nhs.uk
  9. American Diabetes Association. Hypoglycemia (Low Blood Glucose). Checked 25 October 2026. diabetes.org
  10. Monnier L, Colette C, Sardinoux M, Baptista G, Regnier-Marie N, Owens D (2015). The dawn phenomenon in type 2 diabetes: how to assess it in clinical practice? Diabetes & Metabolism, 41(2), 132-137. PMID: 25457475. The authors declared no conflict of interest and no external funding. pubmed.ncbi.nlm.nih.gov/25457475
  11. American Diabetes Association Professional Practice Committee (2026). 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. Diabetes Care, 49(Suppl 1), S132-S149. PMID: 41358894. Duality of interest information is published separately by the ADA (doi.org/10.2337/dc26-SDIS). pubmed.ncbi.nlm.nih.gov/41358894
  12. Diabetes UK. Checking your blood sugar levels (target ranges). Checked 25 October 2026. diabetes.org.uk/about-diabetes/looking-after-diabetes/blood-glucose/target-ranges
  13. Kanaley JA, Heden TD, Liu Y, Whaley-Connell AT, Chockalingam A, Dellsperger KC, Fairchild TJ (2024). Temporal optimization of exercise to lower fasting glucose levels. Journal of Physiology, 602(1), 89-101. PMID: 37732475. Funded by US National Institutes of Health grants; the authors declared no competing interests. pubmed.ncbi.nlm.nih.gov/37732475
  14. Dempsey PC, Blankenship JM, Larsen RN, et al. (2017). Interrupting prolonged sitting in type 2 diabetes: nocturnal persistence of improved glycaemic control. Diabetologia, 60(3), 499-507. PMID: 27942799. Funded by the National Health and Medical Research Council of Australia and Diabetes Australia Research Trust; the authors declared no duality of interest. pubmed.ncbi.nlm.nih.gov/27942799
  15. Imai S, Kajiyama S, Hashimoto Y, et al. (2020). Late-night-dinner deteriorates postprandial glucose and insulin whereas consuming dinner dividedly ameliorates them in patients with type 2 diabetes: a randomized crossover clinical trial. Asia Pacific Journal of Clinical Nutrition, 29(1), 68-76. PMID: 32229444. Funded by the Japan Society for the Promotion of Science (JSPS); the authors declared no conflict of interest. pubmed.ncbi.nlm.nih.gov/32229444
  16. DailyMed (US National Library of Medicine). Metformin hydrochloride extended-release tablets, prescribing information (set id 96c8a89d-99db-24b1-e053-2a95a90ac2b8). Checked 25 October 2026. dailymed.nlm.nih.gov
  17. Electronic Medicines Compendium (UK). Metformin hydrochloride 500 mg Prolonged-release Tablets (Strides), Summary of Product Characteristics (revised 30 May 2024). Written by the manufacturer. Checked 25 October 2026. medicines.org.uk/emc/product/14339/smpc
Back to blog